最高のホルモン療法医師 - トップ33名の医師

セルダル・トゥルハル博士は、アナドル医療センターにおいて内科腫瘍学および乳癌化学療法を専門とする高度な資格を持つ腫瘍専門医です。多数の国際腫瘍学会の会員であり、国際学術誌において多数の論文を発表しています。消化管悪性腫瘍の予後因子および治療を専門としています。トゥルハル博士の診察をご希望の方は、Bookimedよりご予約をお申し込みください。

ハジェテペ大学癌研究所にてフェローシップ研修を修了したソラク医師は、複数の癌種に対するホルモン療法を専門としています。

• 乳癌、精巣癌、卵巣癌、肺癌を担当
• イスタンブール・シシリ・エトファル研修病院にて研修修了
• テキサス大学MDアンダーソン癌センターにて研修
• 消化器癌および頭頸部癌の専門家

ホルモン療法を専門とする外科腫瘍学の専門医 – パストラナ医師は、ガレニア病院において外科的精度とホルモン治療の専門知識を組み合わせた診療を行っています。

• Conacemによる認定資格を取得し、2030年まで有効
• メキシコ腫瘍学会（SMEO）会員
• 2020年よりアナワク医科大学にて大学教員として従事
• セントロ・メディコ・ナシオナル20デノビエンブレにて研修修了

ペレス・シャロン医師は、ソウラスキー医療センター（イキロフ）においてホルモン療法を専門とし、がん治療に関する臨床研究に顕著な貢献をしています。

• 豊富な経験を持つ、高く評価された腫瘍専門医
• 臨床試験に対する腫瘍患者の意識に関する研究を実施
• ホルモン療法を含む幅広いがん治療を提供
• イスラエルの主要医療センターに勤務

オフェル・メリムスキー教授は、数十年にわたる専門的な経験を持ち、スーラスキー医療センターの軟部組織・骨腫瘍科を率いています。

• ホルモン療法および肉腫治療における 41年の経験 以上の経験
• ワイツマン科学研究所およびサックラー医学部のシニア研究員
• ESMO肉腫グループファカルティのメンバー
• 腫瘍免疫学における先駆的な研究協力

Dr. David Sarid is a specialist in oncology and radiotherapy based in Israel with expertise in chemotherapy, radiotherapy, and biological cancer therapy. He has been educated in the UK, Israel, and Georgia and has written over 30 articles devoted to cancer treatment. He is a lecturer at Tel Aviv University and a member of several medical organizations.

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Education

09 / 2004 – 07 / 2006                Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B

09 / 2006 – 08 / 2008                Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A

10 / 2008 – 05 / 2013                Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A

02/ 2009 – 02/2012                   Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, Germany, Doctoral thesis, grade: summa cum laude

05 / 2018                                      Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg

01 / 2019                                      Board certification: Radiotherapy and Radiation Oncology

03 / 2020                                      Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)

09 / 21 – 08 / 23                         MHBA, Friedrich Alexander University, Nuernberg, Germany

07 / 2022                                      Completion of ISO 9001:2015 training, Nicosia, Cyprus

Professional Career

09 / 2013 – 01 / 2019               Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency                                                

07 / 2017 – 07 / 2020               Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist

Since 06 / 2019                          Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant

01 / 2021 – 12 / 2022                Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist

01 / 2021 – 12 / 2021                 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany

Since 01 / 2022                         Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader

Since 01 / 2022                          German Medical Institute, Limassol, Cyprus, Vice Medical Director

Professional Memberships and Distinctions

2010           Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany      

2017           Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany

2019           Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany

2020           Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)

2020           Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)

2021           Invited member of the ESTRO-ACROP guideline committee for prostate cancer

2021           Best Abstract, EMUC congress 2021, Athens, Greece

2023           Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation

2023           Invited member of the ESTRO focus group “Urology”

イェシム・イルドゥルム教授は、がん免疫療法および分子標的治療を専門とし、腫瘍内科学分野において80本以上の論文を発表しています。

• 欧州臨床腫瘍学会（ESMO）会員
• 乳がん、消化器がん、肺がんの専門家
• イスタンブール・ハリチ大学教授
• ロンドンのメラノーマおよび腎がんクリニックにて高度専門研修を修了

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

アリ・ラファエル教授――テルアビブ・スラスキー医療センター（イキロフ、テルアビブ）トランスレーショナル腫瘍学部門長および臨床がん研究部門研究員。患者一人ひとりのニーズに寄り添う個別対応のアプローチが高く評価されています。

資格および患者への貢献：

• 腫瘍科デイホスピタルを統括し、国家ゲノム医療プロジェクトを主導。最先端の研究へのアクセスを提供しています。

• 主任副研究者および主任研究者として、腫瘍内mRNA投与やウイルス製剤を含むフェーズI〜IIIの多数の臨床試験に携わってきました。患者は革新的な治療法への参加機会を得られます。

• 米国および英国における国際的な臨床経験を有し、世界水準の治療基準と先進的なプロトコルの適用を保証しています。

• 国際学術団体の会員（ESMO、IASLC、ISLB、ISCORT、Israeli Medical Association）。最新の治療基準を活用し、国際的な研究に参画しています。

• 　ICH GCP R2、Israeli MOH Guidelinesをはじめ、インフォームドコンセント、副作用管理および患者安全に関する最新課程を含む国際臨床実践基準に基づき、定期的に専門知識の更新および研修を実施しています。

ラファエル教授は、精密な治療レジメンの選択、革新的手法の導入、そして細やかな患者対応により高い信頼を得ており、治療のすべての段階において患者が安心して療養に臨める環境を提供しています。

アスクレピオス・バルムベック病院乳腺病理センター長のシュルツ私講師医学博士は、ハンブルクにおける乳癌患者の4人に1人を診療しています。治療は最新の臨床基準に準拠しています。

アスクレピオス・バルムベック病院の乳腺センターは、FOCUS誌により5年連続でドイツ最優秀施設の一つに選出されています。この評価は乳癌治療に関するものです。

シュルツ私講師医学博士および副センター長のホッフェレ医学博士は、毎月50名以上の患者に手術を行っています。

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。

同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。

主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

 Posts and Affiliations

Clinical Director – Multidisciplinary Breast Unit Kliniken Essen-Mitte, Germany

Lead Breast Cancer Research Program, Kliniken Essen-Mitte

Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)

 Additional Roles

ESMO Faculty – Breast Cancer

Member of AWO Gyn – Commission for plastic and reconstructive surgery

Speaker of the AGIMed – Commission for Integrative Medicine of the AGO

Member of the Organ Commission Mamma of the AGO

Scientific Director of the WSG study group

Global PI, Head of clinical investigations and trials 27

IDMC´s, Steering Boards national and international

Scientific committee of international and national symposia in breast cancer and surgical oncology

 Organization Memberships

Memberships: European Society of Medical Oncology, American Society of Clinical Oncology,

European Academy of Senology, German Cancer Society, German Society of Gynecology and

Obstetrics, Working Group for Gynecological Oncology, German Society of Senology,

 Publications

Peer reviewed Publications: 322

First/Senior Author: 38

h-Index/i10-Index 66/232

Congress Abstracts/Proceedings: 443

Books/Book Chapter: 59

Invited oral Presentations/Lectures: 1032